Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
October 11, 2017 at 10:36 AM EDT
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
